Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

被引:0
|
作者
Tjalf Ziemssen
机构
[1] Technical University of Dresden,Neurological University Clinic
[2] Medical Faculty “Carl Gustav Carus”,undefined
来源
Journal of Neurology | 2005年 / 252卷
关键词
multiple sclerosis; neurodegeneration; neuroprotection; inflammation; treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Historically considered to be an autoimmune demyelinating disease, multiple sclerosis is now recognized to be characterized by significant axonal and neuronal pathology. Addressing this neurodegenerative component of the disease is an important treatment objective, since axonal injury is believed to underlie the accumulation of disability and disease progression. The precise relationship between the inflammatory and neurodegenerative components in multiple sclerosis remains poorly elucidated, although neurodegeneration appears to be at least partially independent from neuroinflammation. The mechanisms underlying axonal injury appear complex and are likely to be multifactorial. Specific treatment strategies need to be developed that act within the central nervous system to prevent neurodegeneration and need to be provided from the earliest stages of disease. It is likely that immunomodulatory treatments acting purely in the periphery will provide only indirect and not direct neuroprotection. A promising approach is to enhance neuroprotective autoimmunity inside the brain, believed to be mediated, at least in part, by the release of neurotrophic factors within the nervous system from infiltrating immune cells. Such a beneficial process would be inhibited by a non-selective immunosuppressive strategy. In summary, treatments of multiple sclerosis should take into account the heterogeneous pathophysiology of the disease. The pathogenic process in the central nervous system itself should be the major focus in multiple sclerosis therapy in order to protect against demyelination and axonal loss and to promote remyelination and regeneration directly in the target tissue, independently of peripheral immune status. In conclusion, selective treatment strategies aimed at preventing axonal injury within the central nervous system are required to complement existing, peripherally acting treatments targeting the immune system.
引用
收藏
页码:v38 / v45
相关论文
共 50 条
  • [41] The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
    Samuel F. Hunter
    James D. Bowen
    Anthony T. Reder
    CNS Drugs, 2016, 30 : 135 - 147
  • [42] Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients
    Lalive, Patrice H.
    Kreutzfeldt, Mario
    Devergne, Odile
    Metz, Imke
    Bruck, Wolfgang
    Merkler, Doron
    Pot, Caroline
    JOURNAL OF NEUROINFLAMMATION, 2017, 14
  • [43] Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod
    Matheus Bernardon Morillos
    Paulo Henrique Pires de Aguiar
    Paulo Roberto Franceschini
    Juliana Ávila Duarte
    Cristian Daniel Piccini
    Alessandro Finkelsztejn
    Neurological Sciences, 2023, 44 : 361 - 363
  • [44] Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report
    Tieppo, Eduardo Macedo de Souza
    da Silva, Tomas Fraga Ferreira
    Araujo, Roger Santana
    Silva, Guilherme Diogo
    Paes, Vitor Ribeiro
    Rimkus, Carolina de Medeiros
    Tinone, Gisela
    Pereira, Samira Apostolos
    Callegaro, Dagoberto
    JOURNAL OF NEUROIMMUNOLOGY, 2022, 373
  • [45] Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis
    Fujii, Takayuki
    Yamasaki, Ryo
    Miyachi, Yukino
    Nagata, Satoshi
    Maimaitijiang, Guzailiayi
    Nakamura, Yuri
    Shinoda, Koji
    Matsushita, Takuya
    Isobe, Noriko
    Kira, Jun-ichi
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 409
  • [46] Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
    Hartung, Hans-Peter
    Cree, Bruce A. C.
    Barnett, Michael
    Meuth, Sven G.
    Bar-Or, Amit
    Steinman, Lawrence
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Role of Sirtuins in Modulating Neurodegeneration of the Enteric Nervous System and Central Nervous System
    Chandramowlishwaran, Pavithra
    Vijay, Anitha
    Abraham, Daniel
    Li, Ge
    Mwangi, Simon Musyoka
    Srinivasan, Shanthi
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [48] Cross-talks between the kidneys and the central nervous system in multiple sclerosis
    Rostami, Sahar
    Emami-Aleagha, Mohammad-Sajad
    Ghasemi-Kasman, Maryam
    Allameh, Abdolamir
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2018, 9 (03) : 206 - 210
  • [49] Therapeutic electrical stimulation of the central nervous system
    Benabid, AL
    Wallace, B
    Mitrofanis, J
    Xia, C
    Piallat, B
    Fraix, V
    Batir, A
    Krack, P
    Pollak, P
    Berger, F
    COMPTES RENDUS BIOLOGIES, 2005, 328 (02) : 177 - 186
  • [50] The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system
    Furlan, R
    Pluchino, S
    Martino, G
    CURRENT OPINION IN NEUROLOGY, 2003, 16 (03) : 385 - 392